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Predictive factors for mortality after open repair of
paravisceral abdominal aortic aneurysm
Prateek K. Gupta, MD,a Jason N. MacTaggart, MD,b Bala Natarajan, MBBS,a Thomas G. Lynch, MD,b
Shipra Arya, MD, SM,a Himani Gupta, MD,c Xiang Fang, MD,d and Iraklis I. Pipinos, MD,b Omaha, Neb
Objective: The use of fenestrated and branched stent graft technology for paravisceral abdominal aortic aneurysms
(PAAA) is on the rise; however, its application is limited in the United States to only a few selected centers. Most PAAAs
are currently repaired using an open approach. The objective of this study was to determine which patients are at highest
risk with open PAAA repair and might benefit most from endovascular repair using fenestrated or branched stent grafts.
Methods: This was a retrospective cohort study using data from American College of Surgeons National Surgical Quality
Improvement Program (NSQIP) hospitals. We identified 598 patients (27.5% women) who underwent elective open
PAAA repair from the 2007 to 2009 NSQIP, a prospective database maintained at >250 centers. The main outcome
measure was 30-day postoperative mortality.
Results: The median patient age was 73 years. The 30-day major morbidity rate was 30.1%, and the mortality rate was
4.5%. Major complications included reintubation (10.0%), sepsis (10.7%), return to operating room (9.2%), new dialysis
requirement (5.9%), cardiac arrest or myocardial infarction (4.5%), and stroke (1.2%). Multivariate analyses identified
four predictors of postoperative mortality after open PAAA repair: peripheral arterial disease (PAD) requiring revascu-
larization or amputation, chronic obstructive pulmonary disease (COPD), anesthesia time, and female sex. PAD and
COPD were present in only 5.2% and 20.4% of patients but were associated with a 16.1% and 9.0% mortality rate,
respectively. The mortality rate in women was 7.3% vs 3.5% for men (P  .045).
Conclusions: PAD, COPD, and female sex are major risk factors for postoperative mortality after open PAAA repair.
Fenestrated or branched stent graft repair may be a more valuable alternative to open repair for patients with one or more
of these characteristics who have suitable access vessels. ( J Vasc Surg 2012;55:666-73.)
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aMost infrarenal abdominal aortic aneurysms (AAAs) in
the United States are now treated using an endovascular
approach, resulting in a significant decrease in postopera-
tive morbidity and mortality during the last decade.1 The
minimally invasive nature of endovascular aneurysm repair
(EVAR) allows treatment of a larger population of patients
and results in shorter hospital stays and greater patient
satisfaction compared with open surgery.2
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666Unfortunately, anatomic exclusions remain problem-
tic, and current commercially available stent grafts provide
o means of maintaining perfusion to critical renal and
esenteric arteries if they are involved in the aneurysmal
rocess, as is seen in approximately 15% of all AAAs.3
istinct from infrarenal AAAs, these paravisceral AAAs
PAAAs) carry greater morbidity andmortality rates and are
sually treated with open surgery throughout the coun-
ry.4,5 In a few specialized centers with access to advanced
echnology, selected patients with PAAAs are offered
VAR using fenestrated and branched stent grafts. These
ustom-designed and manufactured prostheses use side
oles or branches to maintain visceral blood flow while
xcluding the adjacent aneurysm from the circulation.
Although long-term outcomes of fenestrated and
ranched EVAR are still uncertain, an increasing experi-
nce demonstrates good patient and device-related short-
erm results.3-9 With limited availability of this advanced
echnology and expertise, clinicians now face a predicament
f properly selecting patients for fenestrated and branched
VAR in lieu of open repair. To our knowledge, there are
o evidence-based criteria or guidelines to help a clinician
ecide when to refer patients with PAAAs to specialty
enters for fenestrated or branched stent graft consider-
tion. A reasonable initial approach to this problem is to
eserve the fenestrated and branched stent graft treatment
or patients who are at high risk for open repair. Single-
enter studies to date have not elicited preoperative risk
actors associated with increased postoperative mortality
fter open repair of PAAA due to small sample size.4,5,10-13ence, we used the multicenter, clinical, prospective Na-
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data sets to assess the preoperative risk factors for 30-day
mortality after elective open PAAA repair.
METHODS
NSQIP data set. Data were extracted from the 2007,
2008, and 2009 NSQIP Participant Use Data Files
(PUF).14 These are multicenter, prospective databases with
183 (year 2007), 211 (year 2008), and 237 (year 2009)
participating academic and community U.S. hospitals. In
NSQIP, a participant hospital’s surgical clinical nurse re-
viewer (SCNR) captures data on 136 perioperative vari-
ables using a variety of methods, one of which is medical
record abstraction. The data are collected based on strict
criteria formulated by a committee. To ensure the data
collected are of a high quality, the NSQIP has developed
different training mechanisms for the SCNR and conducts
an inter-rater reliability audit of participating sites.14 The
processes of SCNR training, inter-rater reliability auditing,
data collection, and sampling methodology have been pre-
viously described in detail.14
Patients. Patients undergoing an elective open opera-
tion for unruptured PAAA (AAA involving the visceral
mesenteric, celiac, or renal vessels) were identified from the
NSQIP data sets using the American Medical Association’s
Current Procedural Terminology (CPT) code for the pro-
cedure (35091) and International Classification of Diseases
(ICD)-9th Edition code (441.4). Type IV thoracoabdomi-
nal aneurysms (ICD code 441.7) were not included in our
analysis.
Preoperative data included demographic, lifestyle, co-
morbidity, and other variables. Demographic variables in-
cluded age, sex, and race. Lifestyle variables included a
history of smoking (1 year of surgery) and alcohol use
(2 drinks a day in the 2 weeks before surgery). Comor-
bidities included presence or absence of renal disease (dial-
ysis dependence), coronary artery disease (angina30 days
of surgery, myocardial infarction [MI] 6 months of sur-
gery, prior percutaneous coronary intervention, and prior
cardiac surgery), congestive heart failure, hypertension,
peripheral arterial disease requiring previous revasculariza-
tion or amputation (PAD), rest pain in lower extremity,
history of chronic obstructive pulmonary disease (COPD),
neurologic event or disease (stroke with or without residual
deficit, transient ischemic attack, and hemiplegia), diabetes
mellitus, chronic corticosteroid use, weight loss of10% in
the 6 months before surgery, bleeding disorders, and open
wound.
Other factors considered were American Society of
Anesthesiologists class,15 admission status (from home vs
facility), preoperative functional status (defined as ability to
perform activities of daily living in the 30 days before
surgery and assessed as independent, partially dependent,
totally dependent), dyspnea (none, moderate exertion, at
rest), prior surgery 30 days, do not resuscitate status
before operation, disseminated cancer, and body mass in-
dex. Complete definitions for all the above listed variables
have been previously published elsewhere.14 aPreoperative laboratory variables analyzed included
lood urea nitrogen, creatinine, albumin, bilirubin, hemat-
crit, platelet count, serum glutamic oxaloacetic transami-
ase, white blood cell count, partial thromboplastin time,
nd prothrombin time. Laboratory values were categorized
s normal and abnormal using NSQIP definitions; and
issing data constituted a third categoric level, an indicator
ariable.16
Intraoperative data analyzed included wound classifica-
ion (clean, clean contaminated, contaminated, dirty),
ntraoperative transfusion, operative time, time under an-
sthesia, visceral revascularization (bypass or replantation
f the visceral artery from/to the aorta), and intraoperative
omplications.
Outcome. The primary outcome of interest was peri-
perative mortality. Other outcomes analyzed included
ospital length of stay, minor morbidity (urinary tract
nfection or superficial wound infection), and major mor-
idity. The latter included deep wound infection, organ
pace infection, wound dehiscence, pneumonia, reintuba-
ion, ventilator requirement 48 hours, pulmonary em-
olus, deep venous thrombosis, renal insufficiency, acute
enal failure, stroke, coma, peripheral nerve deficiency,
raft or prosthesis failure, cardiac arrest, MI, transfusion
4 units packed red blood cells 72 hours, sepsis, septic
hock, or return to the operating room. The NSQIP data-
ase captures outcomes through 30 days after surgery,
xcept for hospital length of stay, which is recorded until
he patient is discharged.
Statistical analysis. Univariate exploratory analysis
as performed using Pearson 2 test or the Fisher exact test
or categoric variables and t or F test for continuous vari-
bles. Multiple logistic regression modeling was performed
o assess risk factors for perioperative morbidity and mor-
ality. The model selection was based on a stepwise proce-
ure, which alternates between dropping the least signifi-
ant variable from the model and then reconsidering all
otential variables for reintroduction into the model until
o more variables can be added. A variable that is individ-
ally predictive of adverse events may not be selected by the
tepwise procedure when adding the variable does not
ignificantly improve the predictive power of the existing
odel. The C statistic and the P value for the Hosmer-
emeshow test were obtained to determine if there was a
atisfactory fit of themodel.Median data are presented with
he lower quartile (QL)-upper quartile (QU). All statistical
nalyses were performed using SAS 9.2 software (SAS
nstitute, Cary, NC). A value of P  .05 was considered
ignificant.
ESULTS
Demographics, comorbidities, and therapy chara-
teristics. In the 2007 to 2009 NSQIP data set, 598
atients (4.6% of total AAAs in the data set), comprising
33 men (72.4%) and 165 women (27.6%). underwent
lective open operation for unruptured PAAA. The median
ge was 73 years (QL-QU, 66-78 years).
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27). The minor complication rate was 5.5% (n  33), and
the major morbidity rate was 30.1% (n  180). Fifty-five
patients (9.2%) required reoperation 30 days. Median
hospital length of stay was 7 days (QL-QU, 6-10 days). The
demographic characteristics, preoperative risk factors, and
laboratory values are listed in Table I. Postoperative com-
plications are listed in Table II.
Multivariate logistic regression analysis. Preoper-
ative variables significantly associated with postoperative
mortality included PAD, COPD, anesthesia time, and fe-
male sex (Table III). The C statistic for the postoperative
mortality model was 0.79, indicating excellent discrimina-
tion. The Hosmer-Lemeshow goodness-of-fit test pro-
duced a 2 value of 6.28 (P  .6), indicating an excellent
calibration.
Preoperative variables significantly associated with
postoperative morbidity included anesthesia time and in-
traoperative transfusion (Table IV). The C statistic for the
postoperative morbidity model was 0.66, indicating a mod-
est discrimination. The Hosmer-Lemeshow goodness-of-
fit test produced a 2 value of 9.44 (P  .3), indicating an
excellent calibration.
Analysis of risk factors. Of the 598 patients in the
data set, 31 (5.2%) had PAD, and 567 (94.8%) did not have
PAD. Five of the 31 patients (16.1%) with PAD died after
surgery, in contrast to 22 deaths among the 567 patients
(3.9%) without PAD (P  .001). A major complication
occurred after surgery in 15 of 31 patients (48.4%) with
PAD compared with 165 of 567 patients (29.1%) without
PAD (P  .02).
COPD is defined by NSQIP as emphysema or chronic
bronchitis, or both, resulting in any one or more of the
following:
1. Functional disability fromCOPD (eg, dyspnea, inability
to perform activities of daily living),
2. Hospitalization in the past for treatment of COPD and
requiring chronic bronchodilator therapy with oral or
inhaled agents, or
3. A forced expiratory volume in 1 second of 75% of
predicted on pulmonary function testing.
Patients whose only pulmonary disease is asthma, dif-
fuse interstitial fibrosis, or sarcoidosis are not included.
In the data set, 122 patients (20.4%) had COPD, and
476 (79.6%) did not have COPD. Of the 122 patients with
COPD, 11 (9.0%) died after surgery in contrast to 16
deaths among the 476 patients (3.4%) without COPD (P
.007). A major complication after surgery developed in 48
patients (39.3%) with COPD in contrast to 132 patients
(27.7%) without COPD (P  .01).
Women had a mortality rate of 7.3% in contrast to 3.5%
for men (P  .045). The morbidity rate was, however, not
significantly different, at 28.5% for women vs 30.7% for
men (P  .6).
The median (QL-QU) time under anesthesia was 352
minutes (270-424 minutes) for survivors, and 417 minutes
(313-554 minutes) for those who died after surgery (P able I. Preoperative and intraoperative characteristics
ategory Pre-op/intra-op variables
No. (%) or median
(QL-QU)
atients 598 (100)
ardiac Angina 1 mon 10 (1.7)
Cardiac surgery, prior 144 (24.1)
Congestive heart failure 4 (0.7)
Myocardial infarction 6 mon 8 (1.3)
PCI, prior 117 (19.6)
irculatory Bleeding disorder 45 (7.5)
Peripheral arterial diseasea 31 (5.2)
Rest pain in lower extremity 7 (1.2)
Wound, open 12 (2.0)
eneral Age, years 73 (66-78)
ASA class
1 8 (1.3)
2 170 (28.4)
3 311 (52.0)
4 108 (18.1)
5 1 (0.2)
Body mass index, kg/m2 27.7
Corticosteroid use, chronic 14 (2.3)
Diabetes mellitus
On insulin 42 (7.0)
On medication 24 (4.0)
Disseminated cancer 5 (0.8)
Do not resuscitate, pre-op 3 (0.5)
Functional status
Partially dependent 10 (1.7)
Totally dependent 0 (0)
Hypertension 514 (86.0)
Prior operation 30 days 5 (0.8)
Race
American Indian 2 (0.3)
Asian/Pacific Islander 3 (0.5)
Black 19 (3.1)
Hispanic 9 (1.5)
Unknown 28 (4.7)
White 537 (89.8)
Sex
Male 433 (72.4)
Female 165 (27.6)
Transition admitted from
Home 583 (97.5)
Acute care 10 (1.7)
Chronic care 3 (0.5)
Others 2 (0.3)
Weight loss 10% within 6
mon
11 (1.8)
aboratory Albumin
Abnormal 62 (10.4)
Normal 218 (36.5)
Unknown 318 (53.2)
Alkaline phosphatase
Abnormal 21 (3.5)
Normal 251 (42.0)
Unknown 326 (54.5)
Bilirubin
Abnormal 14 (2.3)
Normal 251 (42.0)
Unknown 333 (55.7)
Blood urea nitrogen
Abnormal 231 (38.6)
Normal 330 (55.2)
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06 minutes (311-480 minutes) among patients who de-
eloped a major morbidity after surgery and 340 minutes
262-405 minutes) for those who did not (P  .001).
Median (QL-QU) intraoperative red blood cell transfu-
ion was 3 units (1-6 units) for those who developed major
ostoperative morbidity and 2 units (1-3 units) for those
ho did not (P  .001).
ISCUSSION
The minimally invasive surgical revolution came to
ortic surgery with a landmark report by Parodi et al in
991,17 triggering a paradigm shift in AAA repair. The
bvious benefits of prosthesis delivery through easily ex-
osed remote-access arteries and the elimination of aortic
ross-clamping gave rise to a widespread increase in the use
f stent grafts in the years to follow. By 2005, EVAR
able II. Postoperative characteristics
ostoperative variables
No. (%) or median
(QL-QU)
atients 598 (100)
ajor complications
ardiac
Cardiac arrest 18 (3.0)
Myocardial infarction 9 (1.5)
irculatory
Post-op PRBC transfusion 4 U 20 (3.3)
raft
Graft/prosthesis failure 8 (1.3)
nfection
Organ space infection 5 (0.8)
Sepsis 27 (4.5)
Septic shock 37 (6.2)
eurologic
Coma 1 (0.2)
Nerve deficit 0 (0)
Stroke 7 (1.2)
enal
Acute renal failure 35 (5.9)
Renal insufficiency 27 (4.5)
espiratory
Pneumonia 51 (8.5)
Reintubation 60 (10.0)
Ventilator 48 hours 83 (13.9)
eturn to operating room 5 (9.2)
enous thromboembolism
Deep venous thrombosis 11 (1.8)
Pulmonary embolism 2 (0.3)
ound
Deep wound infection 3 (0.5)
Wound dehiscence 9 (1.5)
ny major morbidity 180 (30.1)
inor complications
Superficial wound infection 11 (1.8)
Urinary tract infection 23 (3.9)
ther postoperative variables
Days from operation to death 5 (2-13)
Length of stay 7 (6-10)
Mortality 27 (4.5)
RBC, Packed red blood cells; QL, lower quartile; QU, upper quartile.Table I. Continued
Category Pre-op/intra-op variables
No. (%) or median
(QL-QU)
Creatinine
Abnormal 101 (16.9)
Normal 487 (81.4)
Unknown 10 (1.7)
Hematocrit
Abnormal 108 (18.1)
Normal 478 (79.9)
Unknown 12 (2.0)
Platelets
Abnormal 108 (18.1)
Normal 471 (78.8)
Unknown 19 (3.2)
Prothrombin time
Abnormal 131 (21.9)
Normal 298 (49.8)
Unknown 169 (28.3)
Partial thromboplastin time
Abnormal 48 (8.0)
Normal 398 (66.6)
Unknown 152 (25.4)
SGOT
Abnormal 27 (4.5)
Normal 260 (43.5)
Unknown 311 (52.0)
Sodium
Abnormal 66 (11.0)
Normal 518 (86.6)
Unknown 14 (2.3)
White blood cell count
Abnormal 50 (8.4)
Normal 529 (88.5)
Unknown 19 (3.2)
Neurologic Hemiplegia 10 (1.7)
Stroke
With neurologic deficit 31 (5.2)
Without neurologic
deficit
24 (4.0)
Transient ischemic attack 57 (9.5)
Renal On dialysis pre-op 1 (0.2)
Respiratory COPD 122 (20.4)
Dyspnea
At rest 4 (0.7)
On moderate exertion 138 (23.1)
Social Alcohol intake within last 2
wks
35 (5.9)
Smoking within past year 253 (42.3)
Intraoperative Revascularization 60 (10.0)
Wound classification
1 554 (92.6)
2 29 (4.9)
3 12 (2.0)
4 3 (0.5)
Intra-op PRBC
transfusion, U
2 (1-4)
Anesthesia time, min 354 (274-427)
Operative time, min 237 (181-309)
ASA, American Society of Anesthesiologists; COPD, chronic obstructive
pulmonary disease; PCI, percutaneous coronary intervention; PRBC,
packed red blood cells;QL, lower quartile;QU, upper quartile; SGOT, serum
glutamic oxaloacetic transaminase.ccounted for 56% of infrarenal AAA operations but only
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elective AAA repair (open and EVAR combined) decreased
significantly from 4% to 3.1%, with the 30-day mortality
after open repair (4.8%) being markedly higher than after
EVAR (1.6%).1,18
Although mortality associated with infrarenal AAA has
decreased during the last decade, mortality after elective
PAAA repair continues to remain high. In the two largest
single-center series published to date, perioperative mortal-
ity was 2.5% (6 of 247)5 and 5.8% (15 of 257).4 In other
single-center reports, perioperative mortality has varied
from 0.8% to 6.0%.3,11-13 In our NSQIP analysis presented
here, the 30-day mortality was 4.5%, similar to these previ-
ous single-center reports. The high death and complication
rates associated with PAAA repair likely are due to the
requirement for invasive surgical exposure and the need for
extensive arterial clamping. The increased difficulty of
PAAA repair is well known and often reflected as longer
operations with more blood loss. Indeed, in our analysis,
we found a positive association between increasing opera-
tive times and transfusion requirements with the develop-
ment of major postoperative morbidity.
Outcomes after open elective PAAA repair have not
improved appreciably during the last decade. Furthermore,
as experience with open repair of AAAs declines, outcomes
after open PAAA repair may actually get worse. These
realizations have led to a number of creative approaches
incorporating endovascular techniques to repair these an-
eurysms.
Hybrid repairs involve debranching the abdominal
aorta and using open surgical bypasses to preserve visceral
flow and allow for conventional stent graft placement in the
paravisceral aorta.19 Morbidity and mortality rates after
debranching procedures are not significantly different than
those after open surgery, with recent results from North
Table III. Variables associated with postoperative
mortality in the stepwise logistic regression analysis
Variable Adjusted OR 95% Wald CI
PAD 6.58 2.12-20.41
COPD 3.17 1.39-7.25
Female sex 2.40 1.02-5.66
Time under anesthesia 1.004 1.001-1.007
CI, Confidence interval; COPD, chronic obstructive pulmonary disease;
OR, odds ratio; PAD, peripheral arterial disease with history of revascular-
ization or amputation.
Table IV. Variables associated with postoperative
morbidity in the stepwise logistic regression analysis
Variable Adjusted OR 95% Wald CI
Intraoperative PRBC transfusion 1.10 1.03-1.17
Time under anesthesia 1.003 1.002-1.005
CI, Confidence interval; OR, odds ratio; PRBC, packed red blood cells.American Complex Abdominal Aortic Debranching (NA- lAAD) registry demonstrating 10% perioperative mortal-
ty.20
The chimney, or snorkel technique, is another alterna-
ive to open surgery using off-the-shelf commercially avail-
ble stents and stent grafts.21 With this method, adjunctive
tenting creates a channel alongside the main body stent
raft to maintain perfusion of vital aortic branches when
eployment of the main aortic endograft intentionally cov-
rs the ostia of the vital branches.22 Use of this technique
as shown a reduction in perioperative morbidity; however,
significant reduction in mortality has not been shown.21
ome consider this technique primarily a bailout proce-
ure, because the long-term durability of these repairs is
nknown.
A more refined approach to PAAA repair uses fenes-
rated or branched stent grafts.23 Fenestrated grafts have
einforced apertures in the stent graft fabric that are aligned
ntraoperatively and adjoined to the respective visceral ar-
ery orifice with balloon-expandable stent grafts.24
ranched grafts have cuffs that secure the main body stent
raft to the bridging stent graft that is separately placed into
he visceral artery.25 Fenestrated and branched endografts
re still not approved in the U.S. outside of specialized
esearch protocols, but results appear promising, with peri-
perative mortality rates close to 1%.7-9,26
Because only a few centers across the world are per-
orming PAAA repair using fenestrated or branched en-
ografts—and even then for a limited number of pa-
ients—it becomes imperative that these patients are
arefully selected. Patients who are at a relatively higher risk
or postoperative adverse events after open PAAA repair
ay benefit more from EVAR using fenestrated or
ranched endografts than patients who are at low risk for
pen repair. With this in mind, we analyzed the NSQIP
ata set to assess preoperative factors that are associated
ith postoperative mortality after open PAAA repair.
PAD, COPD, female sex, and time under anesthesia
ere each associated with higher postoperative 30-day
ortality rate after open PAAA repair. None of the previous
ingle-center studies had found any preoperative factor that
as associated with increased risk for postoperative mortal-
ty after open PAAA repair, probably due to relatively
maller number of patients compared with the current
tudy.4,5,10-13
PAD encompasses such disease contributors as tobacco
se, diabetes, previous MI, heart failure, hypertension, and
besity, and thus, it is not surprising that such patients
ould be at an increased perioperative risk.27 However, it
as still surprising to note the significantly higher periop-
rative morbidity (48.4%) and mortality (16.1%) after open
AAA repair amongst patients with PAD compared with
hose without PAD (29.1% and 3.9%, respectively). Previ-
us studies on coronary revascularization have shown PAD
s independently associated with adverse postoperative out-
omes.28 The worse outcomes of patients with symptom-
tic PAD may be partly explained by the comorbidities
long with less favorable lesionmorphologies and anatomic
imitations in the access and target vessels. Furthermore,
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association of PAD with a systemic inflammatory state may
further worsen the outcomes of any PAAA operation.29
Patients with PAD might seem poor candidates for the
use of fenestrated or branched endografts due to access
issues. In the Zenith Fenestrated AAA Endovascular Graft
multicenter trial, however, 23% of the total patients had
PAD with no reported postoperative mortality or renal
failure.8 Similarly, the French Multicenter data on fenes-
trated aortic endografts demonstrated a mortality of 2.0%,
with 20% of the patients having PAD.30 These data suggest
that the difficulties presented by PAD are less of a factor
when an endovascular approach is used for the care of these
patients. This comparison may be somewhat limited by
unavailability of the exact definition used for PAD in the
fenestrated trials. It is also possible that the PAD patients
who underwent fenestrated grafting were selected to en-
sure adequate access and target vessels. Despite these limi-
tations, the difference in mortality rates between open
(16.1%) and fenestrated (1%-2%) repair is striking and
merits further investigation because patients with PADwho
have suitable access vessels may benefit from referral to the
select centers where endovascular repair for PAAA is per-
formed using fenestrated or branched endografts.
Around the globe, COPD prevalence and mortality are
continuing to rise due to an increase in smoking, particu-
larly by women and adolescents.31 Furthermore, its preva-
lence is higher in surgical patients when compared with
age-matched groups, which is reflected by the fact that
one-fifth of the patients in this study had COPD.32 COPD
is a known risk factor for adverse surgical outcomes in
general and respiratory complications, in particular, be-
cause it leads to the impairment of mucociliary clearance,
increased propensity for arrhythmias, and left ventricular
dysfunction.33 In the current study, patients with COPD
had significantly higher postoperative morbidity (39.3%)
and mortality (9.0%) after open PAAA repair than patients
without COPD (27.7% and 3.4%). These outcomes fare
poorly when compared to outcomes after EVAR using
fenestrated or branched grafts. Specifically, 30% of the
patients in the Zenith Fenestrated AAA Endovascular Graft
multicenter trial,8 40% of the patients in the published
French multicenter fenestrated endograft data,6 26% of the
patients in the Netherlands fenestrated data,9 and 62% of
the patients in the Cleveland Clinic data34 had COPD, with
a 30-day mortality rate of 1% to 2%. Thus, given the high
risk, patients with COPD and suitable access vessels may
benefit from EVAR using fenestrated or branched en-
dografts.
Most the patients undergoing open PAAA repair were
men, a finding seen in previous studies.35 After open PAAA
repair, however, there was a significantly higher association
of female sex with postoperative mortality, but not morbid-
ity. Historically, the natural history and the management of
AAA in women have been associated with worse overall
outcomes.35,36 This is likely related to the significant
anatomic and biologic differences between men and
women.36,37 Women with AAA tend to be older than men my about 5 years, have more comorbidities (heart failure,
ulmonary disease, hypertension, and PAD), and less pre-
perative optimization.37,38 Women tend to have smaller
odies and arteries and a higher incidence of cerebrovascu-
ar and iliac occlusive disease.37 Such anatomic differences
ay lead to increased technical limitations in the perfor-
ance of both open and endovascular operations and may
ead to compromised results.
However, outcomes after use of fenestrated or
ranched endografts may be relatively superior to open
epair, as demonstrated in the Zenith Fenestrated AAA
ndovascular Graft multicenter trial, as well as data from
he Cleveland Clinic and the Netherlands, where 20%, 18%,
nd 13% of the patients, respectively, were women, with
1% mortality.8,9,34 Thus, women with adequate access
essels may benefit from repair using fenestrated or
ranched endografts.
Our finding linking time under anesthesia with elevated
ostoperative 30-day mortality cannot be easily translated
o a preoperative recommendation for the choice of an
pen vs endovascular approach. Longer anesthesia times
robably reflect difficult patient anatomy, the added com-
lexity of redo operations, and the occurrence of intraop-
rative complications; however, time under anesthesia may
lso be influenced by the severity of the patient’s comor-
idities and corresponding need for additional monitoring,
r simply each individual operating team’s pace of work.
hus, it is likely that anesthesia time is a consequence of the
verall challenge each individual patient presents to the
perating team, and further interpretation is difficult from
he data available from the database.
Despite its many strengths, this study has some limita-
ions. Variables analyzed were limited to those recorded by
SQIP. Although the data set is fairly comprehensive, with
50 preoperative variables analyzed, information was not
vailable on preoperative stress tests, echocardiography,
rrhythmia, electrocardiogram, and glomerular filtration
ate. Also unavailable were anatomic data, such as aneurysm
iameter and rate of growth, presence of symptoms due to
he aneurysm, presence of left ventricular dysfunction, and
uration or level of clamp placement. Furthermore, the
eason for return to the operating room, the incidence of
ostoperativemesenteric and spinal cord ischemia, and data
n hospital and surgeon volume were also not available
rom the NSQIP database.
Although the generalizability of these findings may be
estricted to hospitals participating in NSQIP, 25% of
ospitals across the U.S. where AAA repairs are performed
re enrolled in NSQIP.39 Lastly, NSQIP does not record
utcomes 30 days, and so evaluation of long-term out-
omes using these data is not feasible.
ONCLUSIONS
PAD, COPD, and female sex are significant risk factors
or increased postoperative mortality after open PAAA re-
air. Fenestrated or branched stent graft repair may be a
aluable alternative to open repair for patients with one or
ore of these characteristics.
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